Ryvu Therapeutics S.A. (RVU.WA)
PLN 36.5
(-3.95%)
PLN 36.5
(-3.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -57.03 Million PLN | 42.48% |
| 2022 | -99.14 Million PLN | -26.84% |
| 2021 | -78.16 Million PLN | 39.32% |
| 2020 | -128.8 Million PLN | -104.82% |
| 2019 | -62.89 Million PLN | 35.1% |
| 2018 | -96.9 Million PLN | -244.47% |
| 2017 | -28.13 Million PLN | -44.48% |
| 2016 | -19.47 Million PLN | 32.33% |
| 2015 | -28.77 Million PLN | -597.89% |
| 2014 | -4.12 Million PLN | 19.74% |
| 2013 | -5.13 Million PLN | -0.17% |
| 2012 | -5.12 Million PLN | 26.32% |
| 2011 | -6.95 Million PLN | -2012.74% |
| 2010 | -329.39 Thousand PLN | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -49.7 Million PLN | 12.86% |
| 2024 Q2 | -54.61 Million PLN | -9.89% |
| 2023 Q2 | -92.03 Million PLN | 69.17% |
| 2023 Q1 | -298.5 Million PLN | -201.07% |
| 2023 FY | -57.03 Million PLN | 42.48% |
| 2023 Q4 | -57.03 Million PLN | 27.17% |
| 2023 Q3 | -78.31 Million PLN | 14.91% |
| 2022 Q3 | -40.41 Million PLN | 0.43% |
| 2022 Q1 | -60.23 Million PLN | 22.94% |
| 2022 Q2 | -40.58 Million PLN | 32.61% |
| 2022 FY | -99.14 Million PLN | -26.84% |
| 2022 Q4 | -99.14 Million PLN | -145.32% |
| 2021 Q2 | -77.88 Million PLN | 32.57% |
| 2021 Q1 | -115.5 Million PLN | 10.33% |
| 2021 Q3 | -75.18 Million PLN | 3.47% |
| 2021 Q4 | -78.16 Million PLN | -3.97% |
| 2021 FY | -78.16 Million PLN | 39.32% |
| 2020 Q4 | -128.8 Million PLN | 17.46% |
| 2020 Q1 | -38.26 Million PLN | 39.15% |
| 2020 FY | -128.8 Million PLN | -104.82% |
| 2020 Q2 | -28.93 Million PLN | 24.37% |
| 2020 Q3 | -156.05 Million PLN | -439.24% |
| 2019 Q2 | -107.42 Million PLN | -19.6% |
| 2019 Q4 | -62.89 Million PLN | 15.74% |
| 2019 Q1 | -89.82 Million PLN | 7.3% |
| 2019 FY | -62.89 Million PLN | 35.1% |
| 2019 Q3 | -74.63 Million PLN | 30.52% |
| 2018 Q4 | -96.9 Million PLN | 3.42% |
| 2018 FY | -96.9 Million PLN | -244.47% |
| 2018 Q2 | -107.46 Million PLN | 29.88% |
| 2018 Q1 | -153.26 Million PLN | -444.82% |
| 2018 Q3 | -100.33 Million PLN | 6.64% |
| 2017 Q3 | -31.98 Million PLN | 6.57% |
| 2017 Q4 | -28.13 Million PLN | 12.06% |
| 2017 FY | -28.13 Million PLN | -44.48% |
| 2017 Q2 | -34.23 Million PLN | -127.48% |
| 2017 Q1 | -15.05 Million PLN | 22.7% |
| 2016 Q1 | -29.51 Million PLN | -2.57% |
| 2016 FY | -19.47 Million PLN | 32.33% |
| 2016 Q4 | -19.47 Million PLN | 34.23% |
| 2016 Q3 | -29.6 Million PLN | -14.26% |
| 2016 Q2 | -25.9 Million PLN | 12.21% |
| 2015 Q4 | -28.77 Million PLN | 19.14% |
| 2015 Q1 | -32.48 Million PLN | -687.86% |
| 2015 Q2 | -36.36 Million PLN | -11.96% |
| 2015 Q3 | -35.58 Million PLN | 2.15% |
| 2015 FY | -28.77 Million PLN | -597.89% |
| 2014 Q4 | -4.12 Million PLN | -159.92% |
| 2014 FY | -4.12 Million PLN | 19.74% |
| 2014 Q1 | 6.9 Million PLN | 234.42% |
| 2014 Q2 | 7.43 Million PLN | 7.62% |
| 2014 Q3 | 6.88 Million PLN | -7.4% |
| 2013 Q3 | 5.74 Million PLN | 216.39% |
| 2013 Q4 | -5.13 Million PLN | -189.42% |
| 2013 FY | -5.13 Million PLN | -0.17% |
| 2013 Q2 | -4.93 Million PLN | -38.41% |
| 2013 Q1 | -3.56 Million PLN | 30.46% |
| 2012 Q4 | -5.12 Million PLN | 0.0% |
| 2012 FY | -5.12 Million PLN | 26.32% |
| 2011 FY | -6.95 Million PLN | -2012.74% |
| 2010 FY | -329.39 Thousand PLN | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioceltix S.A. | -9.13 Million PLN | -524.32% |
| BIOTON S.A. | 64.81 Million PLN | 188.0% |
| Captor Therapeutics Spolka Akcyjna | -71.92 Million PLN | 20.706% |
| Mabion S.A. | -11.98 Million PLN | -375.711% |
| Molecure S.A. | -56.84 Million PLN | -0.324% |
| NanoGroup S.A. | -537.61 Thousand PLN | -10508.58% |
| Pharmena S.A. | -22.05 Million PLN | -158.583% |
| Poltreg S.A. | -57.75 Million PLN | 1.254% |
| Pure Biologics Spólka Akcyjna | 9.33 Million PLN | 711.155% |
| Synthaverse S.A. | 67.86 Million PLN | 184.035% |
| Urteste S.A. | -512 Thousand PLN | -11039.258% |